Study Evaluating Local Susceptibility Patterns Associated With Tigecycline in Comparison to Other Antibiotics

Completed

• Conditions: Infection

• Registration Number: NCT01311349
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

Various bacterial organisms will be tested in order to compile information regarding the effectiveness of tigecycline against certain bacteria seen in local communities.

Detailed Description

This is a prospective, microbiologic in vitro evaluation which will study the susceptibility of tigecycline in disk diffusion on clinical bacterial isolates collected from inpatients and outpatients. Fourteen hospital centers participated in the program. In vitro efficacy of tigecycline will be determined through the in vitro disk diffusion activity, using FDA breakpoints.

Study Timeline

• Study Start: 2005-12
• Study Completion: 2006-09
• Status Verified: 2009-08
• Study First Submitted: 2009-08-10
• Study First Submitted QC: 2011-03-07
• Last Update Submitted: 2011-03-07
• Study First Posted: 2011-03-09
• Last Update Posted: 2011-03-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1575

Inclusion Criteria

Any protocol-specified microorganism isolated from the samples collected from hospitalized patients and outpatients

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified